Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line
Biological and Pharmaceutical Bulletin · 2026
DOI: 10.1248/bpb.b25-00680 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2026. Verfasst von Keisuke Okamoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Ni…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Rhabdomyosarcoma, Monocarboxylic Acid Transporters, Muscle Proteins. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase, are widely prescribed lipid-lowering agents. Nevertheless, their use is occasionally associated with muscle toxicity, including rhabdomyolysis. Exercise reportedly exacerbates statin-induced muscle injury; however, the underlying mechanisms remain poorly understood. Here, we investigated the role of protein kinase C (PKC) signaling in the development of statin-induced cytotoxicity using a rhabdomyosarcoma-derived cell line (RD cells), with particular emphasis placed on the regulation of monocarboxylate transporter 4 (MCT4), a lactate transporter implicated in intracellular acidification and cytotoxic responses. Treatment with simvastatin, atorvastatin, and fluvastatin reduced RD cell viability in a concentration-dependent manner. Co-treatment with bisindolylmaleimide I (BIM), an inhibitor of PKCα, β, γ, δ, and ε, attenuated statin-induced cytotoxicity and tended to suppress simvastatin-induced MCT4 upregulation. Furthermore, co-treatment with Gö6976, a selective inhibitor of PKCα and β, did not mitigate the simvastatin-induced reduction in cell viability. Small interfering RNA-mediated knockdown of PKCδ significantly rescued simvastatin-induced cytotoxicity. Tamoxifen, a clinically available drug with PKC inhibitory activity, including against the δ isoform, attenuated simvastatin-induced cell injury, paralleling the effects of BIM. Collectively, our findings demonstrate that PKCδ contributes to statin-induced cytotoxicity in rhabdomyosarcoma cells, at least in part by regulating MCT4 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan.
- Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan.
Zitieren
APA
Okamoto, K., Matsui, T., Kikutani, Y., Ueda, H., Furugen, A., Narumi, K., & Kobayashi, M. (2026). Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b25-00680
Vancouver
Okamoto K, Matsui T, Kikutani Y, Ueda H, Furugen A, Narumi K, et al. Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line. Biological and Pharmaceutical Bulletin. 2026. doi:10.1248/bpb.b25-00680
BibTeX
@article{Okamoto2026,
author = {Okamoto, Keisuke and Matsui, Toya and Kikutani, Yurika and Ueda, Hinata and Furugen, Ayako and Narumi, Katsuya and Kobayashi, Masaki},
title = {Involvement of Protein Kinase C Delta and Monocarboxylate Transporter 4 in the Development of Statin-Induced Cytotoxicity in a Rhabdomyosarcoma-Derived Cell Line},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
doi = {10.1248/bpb.b25-00680}
}
EUVIMED